BridgeBio to Unveil Phase 3 Data on Encaleret for ADH1 at ASBMR 2026
Event summary
- BridgeBio will present additional Phase 3 CALIBRATE trial data on encaleret for ADH1 at the ASBMR 2026 Annual Meeting.
- Presentations include patient-reported outcomes, bone turnover effects, and regional family cascade genetic testing findings.
- Poster data will also cover safety profile of infigratinib in achondroplasia.
- ASBMR 2026 Annual Meeting takes place October 9-12, 2026 in Boston, Massachusetts.
The big picture
BridgeBio's presentation of Phase 3 data for encaleret at ASBMR 2026 underscores its focus on developing treatments for rare genetic conditions. The company's decentralized model aims to streamline drug development for small patient populations, addressing an unmet need in the biopharmaceutical industry. The strategic emphasis on patient-reported outcomes and regional genetic testing highlights BridgeBio's commitment to both clinical efficacy and broader patient access.
What we're watching
- Regulatory Strategy
- Whether BridgeBio can leverage Fast Track and Orphan Drug Designations to accelerate encaleret's approval process.
- Clinical Efficacy
- How the Phase 3 data on patient-reported outcomes and bone turnover will impact encaleret's market potential.
- Market Differentiation
- The pace at which BridgeBio can establish encaleret as a leading treatment for ADH1 in a competitive landscape.